Health Technology Assessment Events


Virtual ISPOR 2021
| Boston | US

Health Technology Assessment News


ISPOR NEWS - New Task Force Report Published

A global expert panel published and updated consolidated health economic evaluation reporting standards (CHEERS). The report, “Consolidated Health Economic Evaluation Reporting Standards 2022 Explanation and Elaboration: A Report of the ISPOR Economic Evaluation Guidelines Good Research Practices Task Force II,” is published in the January 2022 issue of the Society’s official Journal, Value in Health, and replaces previous CHEERS reporting guidance.

North America

HTA-C-NA

Mark Cuban Cost Plus Drug Company announces first health plan partner, Capital Blue Cross [fiercehealthcare.com, October 2022]

Beginning this month, the Pennsylvania-based plan and Mark Cuban's drug company (MCCPDC) will begin to let members and community organizations know about their collaboration and how they can access low-cost drugs. In 2023, Capital Blue Cross members will be able to use their insurance cards at the company's online pharmacy. 

Practical advice for Early Scientific Advice (ESA) in HTA submiss [pharmaphorum.com, September 2022]

A step-by step guide on the benefits, processes, and key considerations involved in the Healthcare Technology Assessment (HTA) Early Scientific Advice (ESA) consultation as part of planning the holistic evidence generation to support the design of an asset.

New Guidance on the Use of Real-World Evidence [pharmtech.com, August 2022]

While randomized controlled trials (RCTs) remain the gold standard for evidence-based medicines to achieve regulatory approval, interest in the use of real-world evidence (RWE) to support regulatory decision-making is growing. RWE provides additional insights pre- and post-marketing regarding the risk-benefit of a medical product in the real-world setting, and the analysis of real-world data (RWD) contained in electronic health records (EHRs), health claims, patient registries, and from patient-generated data can be leveraged by the pharma industry to drive healthcare decisions and support health technology assessment (HTA) decisions. 

Global Expert Panel Publishes Guidance on Deliberative Processes for Health Technology Assessment [ispor.org, June 2022]

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, has published a guidance regarding the establishment or improvement of deliberative processes for health technology assessment (HTA).

The report, titled “Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force,” offers a definition of a “deliberative” process for HTA, and goes on to provide guidance and an accompanying checklist for (1) developing the governance and structure of an HTA program, and (2) informing how the various stages of an HTA process might be managed using deliberation.

Europe

HTA-C-Eur

NICE co-sign international agreement to boost collaboration [nationalhealthexecutive.com, October 2022]

The National Institute for Health and Care Excellence (NICE) have partnered with five other health technology assessment (HTA) bodies in a bid to boost international collaboration in tackling common challenges and taking advantage of shared opportunities.

The Importance of Payers and HTA: How Did We End Up Here? [dovepress.com, September 2022]

The importance of payers and HTA: How did we end up here? In this episode of the Value Insider podcast, host Mike Chambers speaks with Prof. Mike Drummond about Health Technology Assessment (HTA) and how value is defined.

New Regulation on Health Technology Assessment Seeks to Facilitate EU-Level Joint Clinical Assessments From 2025 [jdsupra.com, September 2022]

The new regulation aims to harmonise clinical and scientific aspects of HTA to make innovative health technologies more widely available in the EU.

The EU HTA regulation: a new frontier for access to innovative technologies [europeanpharmaceuticalreview.com, August 2022]

A new health technology regulation is due to be applied to help EU countries determine the effectiveness of novel technologies and decide on pricing and reimbursement by health insurers or health systems. Here, Professor Vincenzo Salvatore and Giuseppe Ragucci from BonelliErede reflect on what this means for the UK and other parts of the world.

NICE makeover: a new look for the UK’s HTAs [pharmaceutical-technology.com, August 2022]

UK health technology assessments (HTA)s enter a new era following changes from the National Institute for Health and Care Excellence (NICE) and diversion from EU standards.

NICE Real-World Evidence Framework [nice.org.uk, June 2022]

The framework aims to advance the use of real-world evidence in our guidance by (1) identifying when we can use real-world data to reduce uncertainties and improve guidance, and (2) describing best-practices for planning, conducting, and reporting real-world evidence studies.


Asia Pacific

HTA-C-AP

Medicines Australia moves quickly to put HTA system reform high on new government’s agenda [thepharmaletter.com, June 2022]

Pharma trade group Medicines Australia has moved quickly to ensure that major reform of Australia’s health technology assessment (HTA) system is high on the new government’s agenda.

Pharma industry bangs the drum for HTA reform in Australia [thepharmaletter.com, May 2022]

The leading Australian trade body for the pharmaceutical industry, Medicines Australia, said it has alerted “hundreds of key stakeholders to get ready to engage” in the next government review of the country’s health technology assessment (HTA) system.

The review session is set to kick off in July, and will come just a couple of months after the country goes to the polls in a general election.


Latin America 


Middle East and Africa

HTAC-MEA

Abu Dhabi health department, AbbVie Biopharmaceuticals ink collaboration pact [arabianbusiness.com, October 2022]

The Department of Health – Abu Dhabi (DoH) signed a collaboration pact with AbbVie Biopharmaceuticals GMBH for manufacturing and clinical research. The two sides will also cooperate on innovation and health technology assessment and medical education. 

 

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×